Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Q7FC
|
||||
Former ID |
DIB000131
|
||||
Drug Name |
Lurtotecan
|
||||
Synonyms |
Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GG-211; GI-147211; GI-147211A; GL-147211C; GW-211
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Ovarian cancer [ICD9: 183; ICD10:C56] | Discontinued in Phase 2 | [545826] | ||
Company |
Glaxo Inc
|
||||
Structure |
Download2D MOL |
||||
Formula |
C28H30N4O6
|
||||
Canonical SMILES |
n12c(c3c(c(c4c(n3)cc3c(c4)OCCO3)CN3CCN(CC3)C)C2)cc2c(c1<br />=O)COC(=O)[C@]2(O)CC.Cl.Cl
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Toposisomerase-1 | Target Info | Inhibitor | [543672] | |
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | DNA replication | ||||
Pathway Interaction Database | Caspase Cascade in Apoptosis | ||||
WikiPathways | Integrated Pancreatic Cancer Pathway | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.